000293318 001__ 293318
000293318 005__ 20250820121129.0
000293318 0247_ $$2pmid$$apmid:39278107
000293318 0247_ $$2doi$$aDOI:10.1016/j.ebiom.2024.105341 
000293318 0247_ $$2doi$$aDOI:10.1016/j.ebiom.2024.105341
000293318 0247_ $$2altmetric$$aaltmetric:167749718
000293318 037__ $$aDKFZ-2024-01871
000293318 041__ $$aEnglish
000293318 082__ $$a610
000293318 1001_ $$aWang, Sabrina E$$b0
000293318 245__ $$aCirculating inflammatory and immune response proteins and endometrial cancer risk: a nested case-control study and Mendelian randomization analyses.
000293318 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2024
000293318 3367_ $$2DRIVER$$aarticle
000293318 3367_ $$2DataCite$$aOutput Types/Journal article
000293318 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1726571726_12012
000293318 3367_ $$2BibTeX$$aARTICLE
000293318 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000293318 3367_ $$00$$2EndNote$$aJournal Article
000293318 520__ $$aInflammation and immune dysregulation are hypothesized contributors to endometrial carcinogenesis; however, the precise underlying mechanisms remain unclear.We measured pre-diagnostically 152 plasma protein biomarkers in 624 endometrial cancer case-control pairs nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. Odds ratios (ORs) were estimated using conditional logistic regression, accounting for confounding and multiple comparisons. Proteins considered as associated with endometrial cancer risk were further tested in a two-sample Mendelian randomization (MR) analysis using summary data from the UK Biobank (n = 52,363) and the Endometrial Cancer Association Consortium (12,270 cases and 46,126 controls).In the EPIC nested case-control study, IL-6 [OR per NPX (doubling of concentration) = 1.28 (95% confidence interval (CI) 1.03-1.57)], HGF [1.48 (1.06-2.07)], PIK3AP1 [1.22 (1.00-1.50)] and CLEC4G [1.52 (1.00-2.32)] were positively associated; HSD11B1 [0.67 (0.49-0.91)], SCF [0.68 (0.49-0.94)], and CCL25 [0.80 (0.65-0.99)] were inversely associated with endometrial cancer risk; all estimates had multiple comparisons adjusted P-value > 0.05. In complementary MR analysis, IL-6 [OR per inverse-rank normalized NPX = 1.19 (95% CI 1.04-1.36)] and HSD11B1 [0.91 (0.84-0.99)] were associated with endometrial cancer risk.Altered IL-6 signalling and reduced glucocorticoid activity via HSD11B1 might play important roles in endometrial carcinogenesis.Funding for IIG_FULL_2021_008 was obtained from Wereld Kanker Onderzoek Fonds (WKOF), as part of the World Cancer Research Fund International grant programme; Funding for INCA_15849 was obtained from Institut National du Cancer (INCa).
000293318 536__ $$0G:(DE-HGF)POF4-313$$a313 - Krebsrisikofaktoren und Prävention (POF4-313)$$cPOF4-313$$fPOF IV$$x0
000293318 588__ $$aDataset connected to DataCite, PubMed, , Journals: inrepo02.dkfz.de
000293318 650_7 $$2Other$$aEndometrial cancer
000293318 650_7 $$2Other$$aHSD11B1
000293318 650_7 $$2Other$$aInterleukin-6
000293318 650_7 $$2Other$$aMendelian randomisation
000293318 650_7 $$2Other$$aProteomics
000293318 7001_ $$aViallon, Vivian$$b1
000293318 7001_ $$aLee, Matthew$$b2
000293318 7001_ $$aDimou, Niki$$b3
000293318 7001_ $$aHamilton, Fergus$$b4
000293318 7001_ $$aBiessy, Carine$$b5
000293318 7001_ $$aO'Mara, Tracy$$b6
000293318 7001_ $$aKyrgiou, Maria$$b7
000293318 7001_ $$aCrosbie, Emma J$$b8
000293318 7001_ $$aTruong, Therese$$b9
000293318 7001_ $$aSeveri, Gianluca$$b10
000293318 7001_ $$0P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aKaaks, Rudolf$$b11$$udkfz
000293318 7001_ $$0P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aFortner, Renée Turzanski$$b12$$udkfz
000293318 7001_ $$aSchulze, Matthias B$$b13
000293318 7001_ $$aBendinelli, Benedetta$$b14
000293318 7001_ $$aSabina, Sieri$$b15
000293318 7001_ $$aTumino, Rosario$$b16
000293318 7001_ $$aSacerdote, Carlotta$$b17
000293318 7001_ $$aPanico, Salvatore$$b18
000293318 7001_ $$aCrous-Bou, Marta$$b19
000293318 7001_ $$aSánchez, Maria-Jose$$b20
000293318 7001_ $$aAizpurua, Amaia$$b21
000293318 7001_ $$aPalacios, Daniel Rodriguez$$b22
000293318 7001_ $$aGuevara, Marcela$$b23
000293318 7001_ $$aTravis, Ruth C$$b24
000293318 7001_ $$aTsilidis, Konstantinos K$$b25
000293318 7001_ $$aHeath, Alicia$$b26
000293318 7001_ $$aYarmolinsky, James$$b27
000293318 7001_ $$aRinaldi, Sabina$$b28
000293318 7001_ $$aGunter, Marc J$$b29
000293318 7001_ $$aDossus, Laure$$b30
000293318 773__ $$0PERI:(DE-600)2799017-5$$aDOI:10.1016/j.ebiom.2024.105341$$gVol. 108$$p105341$$tEBioMedicine$$v108$$x2352-3964$$y2024
000293318 8564_ $$uhttps://inrepo02.dkfz.de/record/293318/files/1-s2.0-S2352396424003773-main.pdf
000293318 8564_ $$uhttps://inrepo02.dkfz.de/record/293318/files/1-s2.0-S2352396424003773-main.pdf?subformat=pdfa$$xpdfa
000293318 909CO $$ooai:inrepo02.dkfz.de:293318$$pVDB
000293318 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)4b2dc91c9d1ac33a1c0e0777d0c1697a$$aDeutsches Krebsforschungszentrum$$b11$$kDKFZ
000293318 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)74a6af8347ec5cbd4b77e562e10ca1f2$$aDeutsches Krebsforschungszentrum$$b12$$kDKFZ
000293318 9131_ $$0G:(DE-HGF)POF4-313$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vKrebsrisikofaktoren und Prävention$$x0
000293318 9141_ $$y2024
000293318 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bEBIOMEDICINE : 2022$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0320$$2StatID$$aDBCoverage$$bPubMed Central$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0501$$2StatID$$aDBCoverage$$bDOAJ Seal$$d2023-05-02T08:51:17Z
000293318 915__ $$0StatID:(DE-HGF)0500$$2StatID$$aDBCoverage$$bDOAJ$$d2023-05-02T08:51:17Z
000293318 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bDOAJ : Anonymous peer review$$d2023-05-02T08:51:17Z
000293318 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bEBIOMEDICINE : 2022$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0561$$2StatID$$aArticle Processing Charges$$d2023-08-26
000293318 915__ $$0StatID:(DE-HGF)0700$$2StatID$$aFees$$d2023-08-26
000293318 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x0
000293318 980__ $$ajournal
000293318 980__ $$aVDB
000293318 980__ $$aI:(DE-He78)C020-20160331
000293318 980__ $$aUNRESTRICTED